Study of significance of glycosylated hemoglobin in diabetic patient
Journal Title: International Archives of Integrated Medicine - Year 2016, Vol 3, Issue 4
Abstract
Background: Investigation of the structure and biosynthesis of glycosylated Hemoglobin (HbA1c) in the past decade have provided a means to objectively access the average level of glycemia in diabetic patient. The use of Glycosylated hemoglobin level as integrated index of long term blood glucose level, represent a significant tool in our research and therapeutic armamentarium. In this study, we have estimated glycosylated Hemoglobin (HbA1c) in diabetic and non diabetic person and its relationship with fasting and post prandial blood sugar levels. Materials and methods: In present study, Glycosylated hemoglobin levels were estimated by using cation exchange resin method. The study was conducted from November 2012 to October 2014. Measurement of total HbA1c and blood sugar were carried out at Diabetic research laboratory, Tertiary care centre, Teaching Institute. 110 Non diabetic persons studied as a control, which were proved to be Non diabetic from history, FBS, PPBS, Urine sugar. Persons with family history of diabetes were not included in control group (Group: X). 350 diabetic patients which included new and old cases, IDDM and NIDDM cases, complicated and non complicated cases, among them 241 were having NIDDM and 109 were having IDDM type of diabetes (Group: Y+Z). All cases thoroughly studied and details about personal data, history, clinical examination, laboratory investigations, complication of diabetes and type of treatment were noted. Results: In IDDM, there was higher value of mean GHb (13.13%), than in NIDDM (mean GHB 11.89%). Patients having Insulin therapy had higher value of GHb (13.08%) than with on oral hypoglycemic agents (11.91%) and patients on dietary modification had level 9.44%. There was no significant difference in GHb among patients with complication (12.26%) and patients without complications (12.29%). Conclusion: Glycosylated hemoglobin assay defines an end point as the fuel of diabetic therapy and provides a powerful stimulus to the patients to improve their compliance. Glycosylated hemoglobin assay may provide an alternative method of screening for diabetes.
Authors and Affiliations
Dimpal Modi, Gunvanti B. Rathod, K. N. Delwadia, H. M. Goswami
To evaluate the clinical and etiological profile of patients presenting with pancytopenia in Government Dharmapuri Medical College Hospital, Dharmapuri
Introduction: The frequency of underlying pathology causing pancytopenia varies considerably depending upon various factors including geographic distribution and genetic disturbances. The severity of pancytopenia and the...
Serial CT Scan following Traumatic Brain Injury: Its Significance and Analysis
Introduction: CT plays a key role in accurate diagnosis and important diagnostic tool in the management of traumatic brain injury. Materials and methods: Present study was under taken in the Department of Surgery Gandhi...
Clinical profile of patients presented with acute kidney injury
Background: Acute kidney injury (AKI) is defined as abrupt and rapid decline in renal filtration function. We have studied cases of AKI in which there was no primary renal involvement. Materials and methods: A hospital...
Impact of visual impairment on day-to-day visual functioning: A cross-sectional study among geriatric population in a rural area of West Bengal
Background: Visual impairment is a phenomenon which plagues many a human being be it of any age. It occurs all the more when the concern is the geriatric population. They seem to face many difficulties in their day-to-da...
Triple drug intravenous regional anesthesia is safe and equally effective (0.25% lignocaine plus 1 µg/kg fentanyl + 0.5 mg pancuronium) as compared to standard Bier's block (0.5% lignocaine)
Intravenous regional anesthesia requires a tiny practice to obtain good results and proves economical. We evaluated the efficacy of fentanyl (1 µg/kg) and pancuronium (0.5 mg) in lower doses with 0.25% lignocaine (1.5 mg...